Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using propensity score matched national population cohort
Background Streptococcus pneumonia is a significant cause of morbidity and mortality in adults who are immunocompromised and of advanced age. It is the standard of care to vaccinate all high-risk adults (18-64 years) and adults 65 years and older with 2 pneumococcal vaccines. However, pneumococcal immunization rates remain below the HealthyPeople2020 target goal of 90% nationally and locally.
These Guidelines for managing serious pneumococcal disease in hospitals, care homes, prisons, children's day-care centres and military settings were updated in February 2020, following the introduction of the pneumococcal conjugate vaccine into the national immunisation programme.
ConclusionIn Colombia, Finland, and The Netherlands, countries with diverse epidemiologic and population distributions, switching from a PCV10 to PCV13 program would significantly reduce the burden of IPD in all three countries in as few as 5 years.
To explore whether a prime-boost vaccination strategy, i.e., a dose of pneumococcal conjugate vaccine (PCV) and a dose of 23-valent polysaccharide vaccine (PPV23), enhances antibody response compared to single...
Condition: Pneumonia, Pneumococcal Intervention: Biological: 23-Valent Pneumococcal Polysaccharide Vaccine Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Completed
Publication date: Available online 17 February 2020Source: Journal of Molecular Graphics and ModellingAuthor(s): Julia Liang, Anita Mantelos, Zheng Quan Toh, Stephanie M. Tortorella, Katherine Ververis, Jitraporn Vongsvivut, Keith R. Bambery, Paul V. Licciardi, Andrew Hung, Tom C. KaragiannisAbstractStreptococcus pneumoniae infection can lead to pneumococcal disease, a major cause of mortality in children under the age of five years. In low- and middle-income country settings where pneumococcal disease burden is high, vaccine use is low and widespread antibiotic use has led to increased rates of multi-drug resistant pneumo...
AbstractCommunity-acquired pneumonia (CAP) is the leading cause of death among infectious diseases and an important health problem, having considerable implications for healthcare systems worldwide. Despite important advances in prevention through vaccines, new rapid diagnostic tests and antibiotics, CAP management still has significant drawbacks. Mortality remains very high in severely ill patients presenting with respiratory failure or shock but is also high in the elderly. Even after a CAP episode, higher risk of death remains during a long period, a risk mainly driven by inflammation and patient-related co-morbidities....
A dosing schedule that includes three primary doses of pneumococcal conjugate vaccine (PCV) is associated with fewer breakthrough infections in the first year of life than are schedules with two primary doses, according to a new study of surveillance data.Reuters Health Information
CONCLUSION: Through an interprofessional approach, we were able to achieve durable improvements in key rheumatology quality measures largely by enhancing workflow, engaging non-physician providers and managing practice variation. PMID: 32062597 [PubMed - as supplied by publisher]